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 Does DTC advertising aff ect 
physician prescribing habits?
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EVIDENCE-BASED ANSWER
   yes, but the effect varies by
  condition. Direct-to-consumer 
advertising (DTCA) is associated with both 
higher fi delity to minimum treatment rec-
ommendations for depression and high-
er prescribing levels of antidepressants 
for depression and adjustment disorder 
(strength of recommendation [SOR]: B, 
small randomized controlled trial [RCT]). 
DTCA is also associated with higher pre-
scribing rates for osteoarthritis, allergies, 
and hyperlipidemia (SOR: C, time-series 
analyses). 
No changes in prescribing rates have 
been noted for hypertension and benign 
prostatic hyperplasia (SOR: C, time-series 
analyses). 
Physicians often accommodate re-
quests for DTCA medications (SOR: C, 
4 surveys). In some cases, they wouldn’t 
have considered such prescriptions for 
other similar patients (SOR: C, 3 surveys). 
Evidence summary
An RCT demonstrated increased prescribing 
rates when unannounced, standardized pa-
tients who imitated symptoms of either major 
depression or adjustment disorder requested a 
prescription. In 298 visits, 152 family physicians 
and internists prescribed antidepressants at sig-
nifi cantly diff erent rates when patients mimick-
ing major depression requested brand-specifi c 
(53%), general (76%), or no medication (31%) 
(P<.001). Corresponding rates for adjustment 
disorder were 55%, 39%, and 10% (P<.001). Th e 
study found no diff erence in prescribing rates 
between family physicians and internists or be-
tween male and female physicians. 
For patients presenting with depression, 
physician fi delity to minimum recommend-
ed treatment (defi ned as any combination of 
antidepressants, mental health referral, and 
2-week follow-up) was 90% for patients mak-
ing a brand-specifi c request, 98% for those 
making a general request, and 56% for those 
making no request (P<.001).1 
Patients who ask for DTCA meds 
are more likely to get a prescription
A cross-sectional survey compared prescrib-
ing decisions by 38 US and 40 Canadian phy-
sicians for 1431 patients. Most physicians
fulfi lled requests for DTCA medications 
(US 78%, Canadian, 72%). Patients who re-
quested a DTCA medication were far more 
likely to receive a new prescription (DTCA or 
other) than patients who didn’t (odds ratio 
[OR]=16.9; 95% confi dence interval [CI], 7.5-
38.2). Although DTCA is illegal in Canada, mar-
ket contamination seems likely, because the 
study was done in Vancouver, British Columbia.
US patients made more requests for DTCA 
medications (OR=2.2; 95% CI, 1.2-4.1) than Ca-
nadian patients. When patients made DTCA-
related requests, physicians considered 50% 
of new prescriptions to be only “possible” or 
“unlikely” choices for other similar patients, 
compared with only 12.4% when patients didn’t 
make such requests (P<.001).2 
DTCA drugs often trump other options
A national telephone survey of 3000 adults 
found that 35% of respondents were prompt-
ed by DTCA to discuss the medication or re-
lated health concern at a doctor visit. Of these, 
72.9% reported receiving a new prescription, 
and 43% of them were for the advertised drug.3
In 1 study, 
patients who 
requested 
a direct-to-
consumer 
advertising 
medication were 
far more likely 
to receive a new 
prescription 
(DTCA or other) 
than patients 
who didn’t.
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Physicians often 
accommodate 
a request for 
a direct-to-
consumer 
advertising drug, 
despite other 
equally effective 
options.
References
Another survey of 643 physicians showed 
that 39% of visits infl uenced by DTCA result-
ed in new prescriptions for the advertised 
drug. Physician stated they prescribed the 
DTCA medication because they wanted to:
•   prescribe the most eff ective drug (46%),
•   accommodate the request despite other 
equally eff ective options (48%), or
•   accommodate the request despite more 
eff ective options (5.5%). 
Medications other than the advertised 
drug were prescribed during 22% of DTCA-
infl uenced visits.4
DTCA and prescriptions: Mixed results
A time-series analysis examined the relation-
ship between advertising expenditures for 
several types of drugs and prescriptions writ-
ten from 1992 to 1997.5
Advertising for antilipemic drugs was 
positively associated with prescriptions for 
both antilipemics in general (41 prescrip-
tions for every $1000 of advertising; P=.003) 
and Zocor in particular (23/$1000; P<.001). 
Advertising for antihistamines in general and 
Claritin in particular were both positively 
associated with prescriptions for Claritin 
(general advertising: 24/$1000; P=.004; Clar-
itin-specifi c advertising: 45/$1000; P=.005). 
Advertising for acid-peptic disorder med-
ications was inversely associated with Zantac 
prescriptions (−59 prescriptions/$1000, 
P=.004). Th is fi nding may be related to the 
emergence of, and advertising for, proton 
pump inhibitors during this time. 
No relationship between advertising and 
prescribing was found for antihypertensives or 
medications for benign prostatic hypertrophy. 
More frequent advertising doesn’t 
necessarily mean more prescriptions
Another time-series analysis examined the 
relationship between the frequency of lo-
cal DTCA for cyclooxygenase-2 (COX-2) 
inhibitors and prescriptions for COX-2 in-
hibitors in the corresponding months. 
DTCA was not signifi cantly associated with 
Celebrex prescriptions, but was slightly as-
sociated with Vioxx prescriptions (P=.04, 
10-fold increase in DTCA associ-
ated with a 0.5% increase in prescrip-
tions; P=.04). Practices farther than 
100 miles from a media market and those that 
prescribed Vioxx infrequently were excluded.6 
(In 2004, Vioxx was withdrawn from the US 
and worldwide markets.) 
But patient questions about 
a specifi c ad get results
A survey of 2929 patients regarding the ap-
propriateness of COX-2 inhibitors showed 
that 78% of patients who asked their physi-
cian about a COX-2 advertisement received a 
prescription for a COX-2 inhibitor (instead of 
a nonsteroidal anti-infl ammatory drug) com-
pared with 43% of all other patients.7
Recommendations 
Th e American Medical Association (AMA) 
encourages physicians approached by pa-
tients about advertised medications to ini-
tiate a dialogue in order to enhance the 
patient’s understanding of the underlying 
condition. Request ed medications should be 
prescribed only if indicated and cost eff ec-
tive relative to other options. 
Th e AMA also recommends that physi-
cians report (to the pharmaceutical company 
or the US Food and Drug Administration) ads 
that are inaccurate, incomplete, or imbal-
anced, and ads that don’t enhance patient 
education or encourage patients to have a dis-
cussion with their physician.8                          JFP
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